Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO,.
Cytokinetics, Incorporated announced additional 48-week data from FOREST-HCM , the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy , at the 73rd Annual.
Sotatercept with background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone in the STELLAR trial.
Preparing to launch YUTREPIA™ inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent.
Liquidia Corporation Reports Full Year 2023 Financial Results And Provides Corporate Update menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.